All In Biotech

Drug Trial Radar · NCT05718375

Phase IIb Clinical Trial for the Efficacy and Safety by CU01-1001 for 24 Weeks in Type 2 DM Patients With Albuminuria

A Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel Phase IIb Clinical Trial for the Efficacy Assessment and Safety Evaluation by Treating CU01-1001 for 24 Weeks in Type 2 Diabetic Nephropathy Patients With Albuminuria

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

240

Actual

Start

Feb 14, 2023

Primary completion

Nov 12, 2025

Study completion Nov 12, 2025

Sponsor

Lead sponsor
Curacle Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 8, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of CU01-1001 administered for 24 weeks in type 2 diabetic nephropathy patients with albuminuria.

Conditions

  • Diabetic Nephropathies

Interventions

  • CU01-1001Drug

    CU01-1001

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change rate of urinary albumin/creatinine ratio (UACR) at 24 weeks compared to baselineTime frame: Day 0, 24 weeks

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Pusan National University Hospital

    Busan, South Korea

  • SoonChunHyang University Hospital Cheonan

    Chuncheon, South Korea

  • Daegu Catholic University Medical Center

    Daegu, South Korea

  • Keimyung University Dongsan Hospital

    Daegu, South Korea

  • Kyungpook National University Chilgok Hospital

    Daegu, South Korea

  • Yeongnam University Medical Center

    Daegu, South Korea

  • Daejeon Eulji Medical Center, Eulji University

    Daejeon, South Korea

  • Ajou University Hospital

    Gyeonggi-do, South Korea

  • Hallym University Dongtan Sacred Heart Hospital

    Gyeonggi-do, South Korea

  • Korea University Ansan Hospital

    Gyeonggi-do, South Korea

  • Seoul National University Bundang Hospital

    Gyeonggi-do, South Korea

  • The Catholic University of Korea Bucheon St. Mary's Hospital

    Gyeonggi-do, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Jeonbuk National University Hospital

    Jeonju, South Korea

  • Hallym University Gangnam Sacred Heart Hospital

    Seoul, South Korea

  • Kangbuk Samsung Hospital

    Seoul, South Korea

  • Korea University Guro Hospital

    Seoul, South Korea

  • Kyung Hee University Hospital

    Seoul, South Korea

  • Nowon Eulji University

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • The Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, South Korea

  • Wonju Severance Christian Hospital

    Wŏnju, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.